论文部分内容阅读
诱导性多能干细胞(induced pluripotent stem cells,i PS细胞)是指将一些特定的转录因子转入已分化的成体细胞,使其重编程为形态及功能上类似于胚胎干细胞(embryonic stem cells,ES细胞)的一类细胞。因此,i PS细胞技术避免了传统ES细胞在临床应用方面的道德伦理问题,使其在再生医学、疾病建模、新药筛选等方面具有巨大优势。近年来,i PS细胞技术在血液系统疾病中的研究及应用取得较大突破,包括体外诱导生成造血干/祖细胞、疾病模型的建立及耐药机制的研究、基因治疗单基因遗传病等。该文对i PS细胞诱导重编程技术在血液系统疾病中的最新研究进展进行了综述。
Induced pluripotent stem cells (iPS cells) refer to the transformation of specific transcription factors into differentiated adult cells and their reprogramming to morphologically and functionally similar embryonic stem cells (ESs) Cells) of a class of cells. Therefore, i PS cell technology avoids the ethical problems of traditional ES cells in clinical application, making it a great advantage in regenerative medicine, disease modeling, drug screening and so on. In recent years, i PS cell technology has made great breakthroughs in the research and application of hematological diseases, including the induction of hematopoietic stem / progenitor cells in vitro, the establishment of disease models and the mechanism of drug resistance, gene therapy of single-gene inherited diseases. This review summarizes recent advances in iPS cell-induced reprogramming technology in hematological diseases.